Maravai LifeSciences Holdings

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Maravai LifeSciences reports record earnings, eyes sustainable growth strategies

Maravai LifeSciences delivered strong financial performance in Q4 2022 and full year 2022, with record revenue and robust margins, supported by strategic acquisitions and diversified revenue streams.
While facing challenges such as geopolitical risks and margin fluctuations, the company is well-positioned to capitalize on growth opportunities in the cell and gene therapy market, driven by customer-centric strategies and market stability.
By focusing on sustainable growth, ESG initiatives, and customer adaptation, Maravai aims to maintain its competitive edge and drive long-term value creation for shareholders and stakeholders.
The company's commitment to innovation, market expansion, and operational efficiency underscores its resilience and potential for continued success in the evolving biotechnology landscape.

Maravai LifeSciences reports solid Q1 results amidst market challenges

Maravai LifeSciences delivered strong financial performance in Q1 2023, driven by core business strength and innovation.
While facing challenges in the biotech market and revenue decline, the company is strategically positioned for growth.
Opportunities lie in customer adoption, inorganic growth, and recovery in key markets like China.

Maravai LifeSciences adjusts revenue guidance amidst industry demand weakness

Maravai LifeSciences faces near-term challenges with revenue guidance adjustments but maintains confidence in long-term growth prospects. The company is strategically positioned in mRNA and nucleic acid chemistry, focusing on innovation and cost management strategies to drive future success.

Maravai LifeSciences reports strong Q3 earnings, eyes biotech market growth

Maravai LifeSciences Holdings reported solid Q3 performance, focusing on cost reductions and strategic investments. Despite challenges in customer conversations and limited visibility for 2024, the company remains optimistic about growth opportunities in key markets.

Maravai LifeSciences posts robust Q4 results and targets diversified growth

Maravai LifeSciences delivered strong Q4 results and expects continued growth in 2024 with a more diversified customer base.
The company's focus on innovation, efficiency, and customer commitment positions it well for future success.
While facing revenue challenges in Q1, Maravai's performance in Biologic Safety Testing segment provides stability.
Margin expansion tied to top-line growth and CleanCap technology adoption present promising opportunities for the company.

Maravai LifeSciences reports solid Q1 performance amidst growth strategies

Maravai LifeSciences Holdings navigates Q1 2024 with solid revenue, strategic partnerships, and a focus on growth and innovation.
Despite debt challenges, the company's strong cash position, cost reduction efforts, and margin improvement targets signal resilience and adaptability.
Opportunities in GMP product growth, M&A activities, and customer journey insights position Maravai for continued success and market leadership.
Addressing challenges in debt management, cost optimization, and revenue forecasting will be key to sustaining growth and profitability.

Maravai LifeSciences maintains solid financials and strategic partnerships for growth

Maravai LifeSciences demonstrates financial stability and growth potential with steady revenue guidance.
Operational successes at Flanders facilities and new product offerings enhance market competitiveness.
Challenges in managing costs and maximizing profitability require strategic decision-making.
Strategic partnerships and focus on sustainability present opportunities for market expansion and innovation.

Maravai LifeSciences reports Q3 revenue, lowers 2024 guidance, eyes acquisitions

Maravai LifeSciences Holdings faced challenges in Q3 2024 but showcased strengths in its Nucleic Acid Production segment and strategic initiatives. The company is focused on growth opportunities in mRNA technologies and expanding its product portfolio through acquisitions and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

SAN DIEGO, May 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai)(NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2021. Highlights include:

Maravai Lifesciences Reports First Quarter Financial Results and Updates 2021 Financial Guidance

NanoString Technologies

SmileDirectClub

Shockwave Medical

TG Therapeutics

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More

SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of May.

Maravai LifeSciences Announces Investor Conference Schedule for the Month of May 2021

Maravai LifeSciences Holdings, Inc. (MRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Maravai LifeSciences Holdings, Inc. (MRVI) Upgraded to Buy: What Does It Mean for the Stock?

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2021 financial and operating results after the market closes on Monday, May 10, 2021, and will host a conference call on the same day at 2:00 pm. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 10, 2021

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of a public offering of 20,700,000 shares of Maravai's Class A common stock by certain selling stockholders that was previously announced, including the full exercise of the underwriters' option to purchase up to 2,700,000 additional shares of Class A common stock, at a price of $31.25 per share.

Maravai LifeSciences Announces Closing of Secondary Offering of Class A Common Stock by Selling Stockholders and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of an upsized public offering of 18,000,000 shares of Maravai's Class A common stock by certain selling stockholders that was previously announced, at a public offering price of $31.25 per share. The offering was upsized by 3,000,000 shares of Maravai's Class A common stock from what was previously announced. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 2,700,000 shares of Maravai's Class A common stock, which was upsized from 2,250,000 shares of Maravai's Class A common stock. The offering is expected to close on April 12, 2021, subject to customary closing conditions.

Maravai LifeSciences Announces Pricing of an Upsized Secondary Offering of Class A Common Stock by Selling Stockholders

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai or the Company) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today provided preliminary unaudited revenue and Income from Operations estimates for the quarter ended March 31, 2021.

Maravai LifeSciences Announces Preliminary Unaudited First Quarter Revenues and Income From Operations Range

New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing

Maravai LifeSciences Offers End-to-End mRNA Production with the Launch of TriLink BioTechnologies' Plasmid DNA Manufacturing Services

The stock price of Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) has increased by over 20% pre-market. This is why it happened.

MRVI Stock Price Increases Over 20% Pre-Market: Why It Happened

Maravai LifeSciences Holdings, Inc. (MRVI) CEO Carl Hull on Q4 2020 Results - Earnings Call Transcript

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and the full year ended December 31, 2020. Highlights include:

Maravai LifeSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Initiates 2021 Financial Guidance

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in two upcoming virtual investor conferences.

Maravai LifeSciences Announces March 2021 Investor Conference Schedule

Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics

Maravai LifeSciences Expands Its Intellectual Property Portfolio

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences , Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2020 financial and operating results after the market closes on Tuesday, March 2, 2021, and will host a conference call on the same day at 2:00 pm. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, March 2, 2021

SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters' option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share. The aggregate gross proceeds to Maravai from the offering were approximately $1,863,000,000, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Maravai. Maravai's Class A common stock began trading on the Nasdaq Global Select Market on November 20, 2020 under the symbol "MRVI."

Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Maravai LifeSciences has received a welcome public debut. The company provides a crucial role in drug development and in fact even in the Pfizer/BioNTech vaccine.

Maravai LifeSciences: COVID-19 Beneficiary

SAN DIEGO, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of its upsized initial public offering of 60,000,000 shares of Class A common stock at a public offering price of $27.00 per share, before underwriting discounts and commissions, for gross proceeds of $1,620,000,000. All shares of Class A common stock are being offered by Maravai. The shares are expected to begin trading on the Nasdaq Global Select Market on November 20, 2020, under the symbol “MRVI.” The offering is expected to close on November 24, 2020, subject to the satisfaction of customary closing conditions. Additionally, Maravai has granted the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions.

Maravai LifeSciences Announces Pricing of an Upsized Initial Public Offering

Maravai Life Sciences Holdings (NASDAQ:MRVI) will hit the public markets with perfect timing as it sees its mRNA product used by COVID-19 vaccine makers. The Offering: Maravai Life Sciences plans on selling 50 million shares at a price point of $24 to $27.

News for Maravai LifeSciences Holdings Stock (MRVI)